Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s target price suggests a potential upside of 257.14% from the stock’s previous close.

Several other research firms have also issued reports on ANIX. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Finally, Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Anixa Biosciences currently has an average rating of “Hold” and an average target price of $8.50.

Anixa Biosciences Price Performance

Shares of ANIX traded down $0.05 during midday trading on Tuesday, hitting $2.80. 257,605 shares of the company traded hands, compared to its average volume of 158,646. The stock has a 50-day moving average of $2.78 and a 200-day moving average of $2.94. Anixa Biosciences has a one year low of $2.32 and a one year high of $5.46. The firm has a market cap of $95.26 million, a P/E ratio of -9.03 and a beta of 0.59.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. Sell-side analysts forecast that Anixa Biosciences will post -0.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Amit Kumar acquired 21,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were acquired at an average cost of $2.50 per share, with a total value of $52,500.00. Following the transaction, the chief executive officer owned 630,812 shares in the company, valued at $1,577,030. The trade was a 3.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 26.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $33,000. Cetera Investment Advisers bought a new position in Anixa Biosciences in the fourth quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new position in Anixa Biosciences during the second quarter valued at $37,000. Finally, Millennium Management LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.